Evidence map›Paper›PMID 24436016›Full record

ArticleMedical oncology (Northwood, London, England)2014

HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study.

Dorota Pastuszak-Lewandoska, Anna Bartosińska-Dyc, Monika Migdalska-Sęk, Karolina H Czarnecka, Ewa Nawrot, Daria Domańska, Krzysztof Szyłło, Ewa Brzeziańska

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Alternative splicing in the genome of HPV and its regulation.Frontiers in cellular and infection microbiology · 2024
    Review
  2. Article
  3. Article
  4. E6/E7 and E6Frontiers in immunology · 2019
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dorota Pastuszak-LewandoskaDepartment of Molecular Bases of Medicine, 1st Chair of Internal Diseases, Medical University of Lodz, Pomorska 251, C5, 92-213, Lodz, Poland.
Anna Bartosińska-Dyc
Monika Migdalska-Sęk
Karolina H Czarnecka
Ewa Nawrot
Daria Domańska
Krzysztof Szyłło
Ewa Brzeziańska
Medical University of Lodz · PLPolish Mother’s Memorial Hospital Research Institute · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integration of the HPV genome into a host cell DNA leads to the deregulated overexpression of the viral E6 and E7 oncoproteins, and this is a key factor for progression from low-grade cervical lesions to high-grade lesions and invasive cervical cancer. The aim of our study was to analyze the expression levels of HPV E6*I/E6*II and E7 genes in cervical neoplasia of different grades. The analysis involved 10 low-grade squamous intraepithelial lesions (CIN1), 15 high-grade lesions (CIN2 and CIN3), as well as normal cytology samples (n=10). HPV genotyping was done using RealLine HPV 16/18 kit. The expression analysis was performed in real-time PCR assay using gene-specific primers and SYBR Green. HPV16 DNA was found in 65.71% patients, including also normal cytology samples. The increased expression level of E6*I was observed in 12 (34.3%) patients. The expression of E6*II was increased in 10 (28.6%) samples, and E7 overexpression was found in 14 (40%) patients. Significant positive correlation was observed between the amount of HPV16 DNA and the levels of E6*I and E6*II expression. There were no statistically significant differences in expression levels of the studied genes between the groups (CIN1 vs. CIN2/CIN3 vs. normal cytology). Statistically significant differences were found in CIN2/CIN3 group, with the higher expression of E6*II as compared with E6*I. We suggest that the expression level of E6*II gene might be used as an indicator of cervical cancer severity, in patients with high-grade cervical neoplasia, but these observations need to be confirmed in a larger patient cohort.

Indexed as

AdultAgedCarcinoma, Squamous CellCase-Control StudiesCervix UteriDNA, ViralFemaleFollow-Up StudiesGenotypeHuman papillomavirus 16HumansMiddle AgedNeoplasm GradingOncogene Proteins, ViralPapillomavirus InfectionsPilot ProjectsDNA, ViralE6 protein, Human papillomavirus type 16Oncogene Proteins, ViralRepressor ProteinsRNA, Messenger

Identifiers

PMID24436016
OpenAlexW2025181931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.